Sandeep K. Singh

Dr. Sandeep K. Singh

Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2024 in Polymers
Verified
Journal Article
Open access
PDF file
Ling DingLing Ding
Ling Ding
PAPrachi Agrawal
Prachi Agrawal
Sandeep K. SinghSandeep K. Singh
Sandeep K. Singh
YCYashpal Singh Chhonker
Yashpal Singh Chhonker
JSJingjing Sun
Jingjing Sun
DMDaryl J Murry
Daryl J Murry
Chemotherapy together with surgery and/or radiotherapy are the most common therapeutic methods for treating cancer. However, the off-target effects of chemotherapy are known to produce side effects and dose-limiting toxicities. Novel delivery platforms based on natural and synthetic polymers with enhanced pharmacokinetic and therapeutic potential for the treatment of cancer have grown tremendously over the past 10 years. Polymers can facilitate selective targeting, enhance and prolong circulation, improve delivery, and provide the controlled release of cargos through various mechanisms, including physical adsorption, chemical conjugation, and/or internal loading. Notably, polymers that are biodegradable, biocompatible, and physicochemically stable are considered to be ideal delivery carriers. This biomimetic and bio-inspired system offers a bright future for effective drug delivery with the potential to overcome the obstacles encountered. This review focuses on the barriers that impact the success of chemotherapy drug delivery as well as the recent developments based on natural and synthetic polymers as platforms for improving drug delivery for treating cancer.

24 May 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AUAkanksha Upadhyay
Akanksha Upadhyay
PCPragya Chandrakar
Pragya Chandrakar
SGSampa Gupta
Sampa Gupta
NPNaveen Parmar
Naveen Parmar
Sandeep K. SinghSandeep K. Singh
Sandeep K. Singh
SKSusanta Kar
Susanta Kar

1 May 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AGAnirban Ghoshal
Anirban Ghoshal
AKAjeet Kumar
Ajeet Kumar
DYDoddapaneni Yugandhar
Doddapaneni Yugandhar
Chandan SonaChandan Sona
Chandan Sona
SKSunu Kuriakose
Sunu Kuriakose
ASAjay K. Srivastava
Ajay K. Srivastava

2 August 2016 in RSC Advances
Verified
Journal Article
Closed access
PDF file
SSShweta Sharma
Shweta Sharma
JSJyotsana Singh
Jyotsana Singh
AVAshwni Verma
Ashwni Verma
BTBanala Venkatesh Teja
Banala Venkatesh Teja
RSRavi P. Shukla
Ravi P. Shukla
PMP. R. Mishra
P. R. Mishra
Paclitaxel (PTX) is a first line anti-tumor agent and is widely used in the treatment of breast cancer. However, there are several limitations associated with the drug which hamper its successful clinical application. To address these obstacles we envisaged developing a nanocrystal based formulation that can overcome its limitations and significantly improve its efficacy. In this work paclitaxel nanocrystals with particle size <250 nm were developed and subsequently coated with hyaluronic acid (HA) to impart both long circulating and tumor targeting properties. A systematic cell based in vitro evaluation of HA-PTX/NC on 2D monolayer and 3D spheroids demonstrates that hyaluronic acid coating was able to significantly improve the therapeutic efficacy compared to marketed formulation of PTX (Taxol™). It was observed that interaction of HA-PTX/NC with CD44 receptors played a significant role in enhancing the uptake and thereby efficacy of PTX against cancer cells. In vivo studies revealed that HA-PTX/NC significantly prolonged the blood circulation time of PTX with an increase of 8.4 fold of AUC0–∞ in comparison to Taxol™. Furthermore HA-PTX/NC were found to exhibit higher antitumor efficacy, reduced lung metastasis and reduced toxicity in LA-7 tumor bearing rat model than Taxol™. Findings suggested that anchoring hyaluronic acid on PTX nanocrystals can be a promising approach for anticancer therapy.

13 February 2017 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
Sandeep K. SinghSandeep K. Singh
Sandeep K. Singh
VMVishal Makadia
Vishal Makadia
SSShweta Sharma
Shweta Sharma
Mamunur RashidMamunur Rashid
Mamunur Rashid
SSSudhir Shahi
Sudhir Shahi
JGJiaur R. Gayen
Jiaur R. Gayen

12 August 2016 in Drug Delivery
Verified
Journal Article
Closed access
HAHafsa Ahmad
Hafsa Ahmad
AAAbhishek Arya
Abhishek Arya
SASatish Agrawal
Satish Agrawal
SSSheeba Saji Samuel
Sheeba Saji Samuel
Sandeep K. SinghSandeep K. Singh
Sandeep K. Singh
ADAnil Kumar Dwivedi
Anil Kumar Dwivedi
Withania somnifera Dunal (Solanaceae) known as Ashwagandha, a popular plant of Indian origin is known to possess tremedous medicinal potential, often used as anti-inflammatory, anti-platelet, antihypertensive, hypoglycemic, hypolipidemic and adaptogenic candidate. Some of its chemotypes developed by CSIR, India includes NMITLI-101, NMITLI-118, NMITLI-128. In this study the investigators have attempted development of a phytosomal complex of NMITLI118RT + (standardized ethanolic extract of a new chemotype of W. somnifera Dunal.), its pharmaceutical characterization and evaluation of its neuro-protective potential against experimenal stroke in rats in continuation with their previous work in this area. The phytosomal complex (NIMPLC) was prepared by following a cohesive optimization design and was characterized on the basis of solubility, dissolution profile, FT-IR, DSC-TGA analysis, zeta potential, physical stability, forced degradation and photolytic degradation. Results were suggestive of a pharmaceutically acceptable formulation. NIMPLC was taken up further for biological evaluation using the middle cerebral artery occlusion (MCAO) model in rats. It could be demonstrated that the beneficial effects of NMITLI118RT + could be augmented by NIMPLC in 1 h pre and 6 h post treatment as was evident from reduction in MDA levels, increment in GSH levels, reduction in neurological deficit (ND) scores and reduction in infarct size. The study could successfully demonstrate the beneficial effects of NIMPLC in brain function restoration following stroke.